Filing Flows › Orthopediatrics (KIDS) › Q3 2026 › vs Q2 2026
Orthopediatrics (KIDS) Q3 2026 vs Q2 2026 (quarter over quarter)
Orthopediatrics's revenue rose $2.2M (+3%) from $70.5M in Q2 2026 to $72.7M in Q3 2026. The biggest changes: Scoliosis +$2.3M (+14%); Sports medicine/other −$134K (-13%); Trauma and deformity −$9K (0%).
Orthopediatrics, Q3 2026: revenue $72.7M (+19% year over year), operating margin -5.8%, net loss $5.9M, operating cash flow $4.5M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 2.2% | -4.4% | +6.6 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Trauma and deformity | $52.6M | $52.6M | −$9K | 0% |
| Scoliosis | $19.2M | $16.9M | $2.3M | +14% |
| Sports medicine/other | $866K | $1.0M | −$134K | -13% |
| Revenue | $72.7M | $70.5M | $2.2M | +3% |
| Income tax benefit | $109K | −$234K | $343K | — |
| Net loss | $5.9M | $7.2M | −$1.2M | -17% |
| Costs & expenses | $78.7M | $77.7M | $1.0M | +1% |
| Operating costs | $76.9M | $74.6M | $2.3M | +3% |
| Interest & other, net | $1.8M | $2.9M | −$1.0M | -37% |
| Cost of revenue | $18.7M | $18.1M | $543K | +3% |
| Research & development | $2.5M | $2.3M | $140K | +6% |
| Sales & marketing | $23.1M | $21.3M | $1.8M | +8% |
| General & admin | $32.0M | $32.8M | −$785K | -2% |
| Operating cash sources | $10.4M | $8.1M | $2.3M | +29% |
| Depreciation & amortization | $5.6M | $5.7M | −$85K | -1% |
| Share-based compensation | $4.4M | $4.2M | $228K | +5% |
| Working capital & other | $396K | −$1.8M | $2.2M | — |
| Net loss absorbed | $5.9M | $7.2M | −$1.2M | -17% |
| Operating cash flow | $4.5M | $928K | $3.6M | +386% |
| Free cash flow (OCF − capex) | $1.6M | −$3.1M | $4.7M | — |
| Capital expenditures | $2.9M | $4.0M | −$1.1M | -28% |
Questions
How much did Orthopediatrics's revenue grow quarter over quarter in Q3 2026?
Orthopediatrics's revenue rose $2.2M (+3%) from $70.5M in Q2 2026 to $72.7M in Q3 2026.
What drove Orthopediatrics's revenue change in Q3 2026?
Scoliosis +$2.3M (+14%); Sports medicine/other −$134K (-13%); Trauma and deformity −$9K (0%).